ISCO · International Stem Cell CORP
$0.39
At close · Sep 2
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These circumstances raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$3.04M
Shares
8.00M
ISCO metrics
63 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.39
Market cap
$3.04M
Price action
19 metricsPrice change (1W)
-23.6%
Price change (30D)
+52.8%
Price change (3M)
+124.8%
Price change (6M)
+172.9%
Price change (YTD)
+172.9%
Price change (1Y)
+193.9%
Trailing year
Price change (5Y)
-38.4%
52-week high
$0.51
52-week low
$0.12
Change from 52-week high
-25.1%
Change from 52-week low
+218.4%
Annualized volatility
193.3%
Beta
-0.7
RSI (14D)
51.1
Price vs SMA 50
+38.2%
Price vs SMA 200
+111.0%
Avg volume (3M)
23,243
Relative volume
0.5
Average dollar volume
$7,586
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
8.00M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 312.8%
P / book
—
FCF yield
10.9%
TTM · current market cap
Buyback yield
—
P / FCF
9.1
reciprocal yield 10.9%
P / operating cash flow
8.2
reciprocal yield 12.1%
Earnings yield
-19.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
55.0%
Operating margin
-4.7%
Trailing 12 months
Net margin
-6.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$444,000
Net income (TTM)
−$582,000
Trailing 12 months
Diluted EPS (TTM)
$-0.07
FCF margin
3.5%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+9.3%
Year over year
Net income growth YoY
-155.0%
Revenue (TTM)
$9.51M
Trailing 12 months
EPS growth YoY
-200.0%
Shares change YoY
+0.0%
Year over year
Revenue CAGR (3Y)
+3.6%
Revenue CAGR (5Y)
+5.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-11.5%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
−$272,000
Free cash flow (TTM)
$333,000
Quick ratio
0.4
Interest coverage
-3.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.09M
Latest balance sheet
Cash & equivalents
$1.09M
Total assets
$5.06M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$369,000
Capital expenditures (TTM)
$36,000
R&D (TTM)
$646,000
SG&A (TTM)
—
Stock compensation (TTM)
$250,000
R&D / revenue
6.8%
Stock compensation / revenue
2.6%
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.1%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
45 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged